Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.40 |
| ▸ | CNR1 | P21554 | 3/20 | 0.40 |
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3922705 | 0.91 | ALOX5 (0.44) | ALOX5MAPTMDM2CNR1CNR2 | |
| SCHEMBL3916533 | 0.89 | MDM2 (0.41) | ALOX5MDM2CNR1CNR2PTGER1 | |
| SCHEMBL3921306 | 0.87 | ABL1 (0.40) | MAPTMDM2NOTUMCYP2D6GHSR | |
| SCHEMBL3921571 | 0.85 | CNR1 (0.53) | CNR1CNR2 | |
| SCHEMBL3931105 | 0.83 | CNR1 (0.42) | ALOX5CNR1CNR2HTR2C | |
| SCHEMBL13602493 | 0.82 | CNR1 (0.41) | ALOX5MDM2CNR1CNR2HTR2C | |
| SCHEMBL3931022 | 0.81 | CNR1 (0.43) | ALOX5MDM2CNR1CNR2PDE4B | |
| SCHEMBL4375154 | 0.79 | PTGER1 (0.43) | MAPTCNR1CNR2PTGER1CYP3A4 | |
| SCHEMBL3923408 | 0.79 | NOTUM (0.50) | ALOX5MAPTCNR1PTGER1NOTUM | |
| SCHEMBL3919299 | 0.79 | CNR1 (0.59) | CNR1CNR2PDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1583742-B1 | CB 1 RECEPTOUR INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2009-12-02 | — | — | EP | disclosed |
| US-7579369-B2 | CB 1 receptor inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7294644-B2 | CB 1 receptor inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-20070238754-A1 | Novel CB 1 receptor inverse agonists | MAYWEG ALEXANDER | 2007-10-11 | — | — | US | disclosed |
| EP-1583742-A1 | NOVEL CB 1 RECEPTOUR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-12 | — | — | EP | disclosed |
| US-20040167129-A1 | Novel CB 1 receptor inverse agonists | HOFFMANN-LA ROCHE INC. | 2004-08-26 | — | — | US | disclosed |
| WO-2004060870-A1 | NOVEL CB 1 RECEPTOUR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167129-A1 | Novel CB 1 receptor inverse agonists | CNR1, CNR2, ARRB1 | ALOX5 1729/4885MAPT 4278/4885MDM2 4827/4885 |
| US-20070238754-A1 | Novel CB 1 receptor inverse agonists | CNR1, CNR2, GPR139 | ALOX5 2342/4885MAPT 3966/4885MDM2 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.